Cargando…

Survival Outcomes among Human Epidermal Growth Factor Receptor 2- (HER2-) Positive Breast Cancer Patients at Kenyatta National Hospital

INTRODUCTION: HER2-positive breast cancer is associated with poor outcomes and higher mortality rates than other breast cancer subtypes. The advent of trastuzumab has significantly changed the natural history of HER2-positive breast cancer. However, it is not an affordable treatment option in sub-Sa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tuwei, Gloria, Degu, Amsalu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8694968/ https://www.ncbi.nlm.nih.gov/pubmed/34956679 http://dx.doi.org/10.1155/2021/3115727

Ejemplares similares

Survival outcomes among colorectal cancer patients at Kenyatta National Hospital: A retrospective cohort study
por: Degu, Amsalu, et al.
Publicado: (2022)

Assessment of drug therapy problems among patients with cervical cancer at Kenyatta National Hospital, Kenya
por: Degu, Amsalu, et al.
Publicado: (2017)

Treatment Outcomes and Its Associated Factors Among Adult Patients with Selected Solid Malignancies at Kenyatta National Hospital: A Hospital-Based Prospective Cohort Study
por: Degu, Amsalu, et al.
Publicado: (2022)

Management of Brain Metastases from Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Breast Cancer
por: McGranahan, Tresa M., et al.
Publicado: (2022)

Prevalence and factors associated with preterm birth at kenyatta national hospital
por: Wagura, Peter, et al.
Publicado: (2018)

Axillary response according to neoadjuvant single or dual human epidermal growth factor receptor 2 (HER2) blockade in clinically node‐positive, HER2‐positive breast cancer
por: Cha, Chihwan, et al.
Publicado: (2021)

Assessment of survival outcomes among lung cancer patients at the National and Referral Hospital in Kenya
por: Said, Nur Swaleh, et al.
Publicado: (2023)

Treatment strategies for hormone receptor-positive, human epidermal growth factor receptor 2-positive (HR+/HER2+) metastatic breast cancer: A review
por: Ran, Ran, et al.
Publicado: (2022)

Assessment of patient doses during mammography practice at Kenyatta National Hospital
por: Wambani, JS, et al.
Publicado: (2011)

Prevalence and Predictors of Cisplatin-Induced Peripheral Neuropathy at the Kenyatta National Hospital
por: Ezzi, Mohammed S., et al.
Publicado: (2019)

Non-phosphorylated Tyr-1248 form of human epidermal growth factor receptor 2 (HER2) predicts resistance to trastuzumab therapy and poor disease-free survival of HER2-positive breast cancer patients
por: Ramić, Snježana, et al.
Publicado: (2022)

Gene Expression and miRNAs Profiling: Function and Regulation in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer
por: Sareyeldin, Rasha M., et al.
Publicado: (2019)

Characterization of Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis Among Patients Admitted to Kenyatta National Hospital: A Retrospective Cross-Sectional Study
por: Irungu, Kenneth, et al.
Publicado: (2017)

Therapeutic Strategies for the Management of Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Positive (HR+/HER2+) Breast Cancer: A Review of the Current Literature
por: Thanopoulou, Eirini, et al.
Publicado: (2020)

Impact of the Updated Guidelines on Human Epidermal Growth Factor Receptor 2 (HER2) Testing in Breast Cancer
por: Kim, Min Chong, et al.
Publicado: (2020)

An overview of resistance to Human epidermal growth factor receptor 2 (Her2) targeted therapies in breast cancer
por: Elshazly, Ahmed M., et al.
Publicado: (2022)

Palbociclib Adherence and Persistence in Patients with Hormone Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer
por: Engel-Nitz, Nicole M, et al.
Publicado: (2023)

Serum epidermal growth factor receptor and HER2 expression in primary and metastatic breast cancer patients
por: Asgeirsson, Kristjan S, et al.
Publicado: (2007)

An Unusual Case of Stevens-Johnson/Toxic Epidermal Necrolysis Overlap Syndrome in HER2 (Human Epidermal Growth Factor Receptor 2)-Positive Breast Cancer Patient Treated With Docetaxel
por: Shamloul, Gelan, et al.
Publicado: (2023)

Cytological evaluation of breast lesions in symptomatic patients presenting to Kenyatta National Hospital, Kenya: a retrospective study
por: Nkonge, Ken Munene, et al.
Publicado: (2015)

Human epidermal growth factor receptor 2 (HER2) and the future of bladder carcinoma
por: Sarkis, Julien, et al.
Publicado: (2020)

HER2 Heterogeneity Is Associated with Poor Survival in HER2-Positive Breast Cancer
por: Hosonaga, Mari, et al.
Publicado: (2018)

Assessment of Parents’ Perception of Quality of Pediatric Oncology Inpatient Care at Kenyatta National Hospital
por: Keiza, Eunice Mmbone, et al.
Publicado: (2017)

Screening for congenital fetal anomalies in low risk pregnancy: the Kenyatta National Hospital experience
por: Onyambu, Callen Kwamboka, et al.
Publicado: (2018)

Implementation and performance of the South African Triage Scale at Kenyatta National Hospital in Nairobi, Kenya
por: Wangara, Ali A., et al.
Publicado: (2019)

Outcomes of Children and Adolescents Admitted with Diabetic Ketoacidosis at Kenyatta National Hospital (KNH), Kenya
por: Musoma, Sophie Nyaombe, et al.
Publicado: (2020)

Appropriateness of imaging modality choice by doctors at the Kenyatta National Hospital’s Accident and Emergency Department
por: Ahmed, Salman S., et al.
Publicado: (2022)

Determinants of unintended pregnancy among women attending antenatal clinic at Kenyatta National Hospital.
por: Ojuok, Rose, et al.
Publicado: (2022)

MENINGIOMA-03 FUNCTIONAL OUTCOME AFTER SURGERY FOR INTRACRANIAL MENINGIOMA AT THE KENYATTA NATIONAL HOSPITAL
por: Kagasi, Travor, et al.
Publicado: (2023)

Rare Human Epidermal Growth Factor Receptor 2 (HER-2)-Positive Neuroendocrine Carcinoma of the Breast: A Case Report with 9-Year Follow-up
por: Marijanović, Inga, et al.
Publicado: (2020)

Human Epidermal Growth Factor Receptor 2 (HER2) in Cancers: Overexpression and Therapeutic Implications
por: Iqbal, Nida, et al.
Publicado: (2014)

Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer
por: Siena, S, et al.
Publicado: (2018)

Cardiotoxicity From Human Epidermal Growth Factor Receptor‐2 (HER2) Targeted Therapies
por: Florido, Roberta, et al.
Publicado: (2017)

CDK4/6 inhibitors in hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer: Are we at the finish line?
por: Yam, Clinton, et al.
Publicado: (2018)

Prognostic Factors in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative (HR+/HER2–) Advanced Breast Cancer: A Systematic Literature Review
por: Cuyún Carter, Gebra, et al.
Publicado: (2021)

Treatment Challenges and Survival Analysis of Human Epidermal Growth Factor Receptor 2-positive Breast Cancer in Real World
por: Adusumilli, Praveen, et al.
Publicado: (2017)

The Pan-Immune-Inflammation-Value Predicts the Survival of Patients with Human Epidermal Growth Factor Receptor 2 (HER2)—Positive Advanced Breast Cancer Treated with First-Line Taxane-Trastuzumab-Pertuzumab
por: Ligorio, Francesca, et al.
Publicado: (2021)

Metformin increases survival in hormone receptor-positive, HER2-positive breast cancer patients with diabetes
por: Kim, Hee Jeong, et al.
Publicado: (2015)

Antimicrobial susceptibility pattern of Staphylococcus aureus isolates from clinical specimens at Kenyatta National Hospital
por: Gitau, Wilfred, et al.
Publicado: (2018)

Antimicrobial susceptibility pattern of Acinetobacter isolates from patients in Kenyatta National Hospital, Nairobi, Kenya
por: Musyoki, Victor Moses, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_bm4t2pd6rgcufo8rnllbsvnc2n